SS-31
An investigational mitochondria-targeted peptide, elamipretide, in clinical development.
Research Use Only — Not for Human ConsumptionShort Description
SS-31, known generically as elamipretide, is a mitochondria-targeted peptide developed as an investigational drug candidate, studied in connection with mitochondrial dysfunction in conditions such as Barth syndrome and certain cardiac and age-related diseases.
Current Legal Status (Mauritius)
Tiger Blood Pharmaceuticals is pursuing product registration in the Republic of Mauritius, where pharmaceutical products are regulated by the Pharmacy Board, operating under the Ministry of Health and Wellness pursuant to the Pharmacy Act 1983. SS-31 (elamipretide) is not currently registered as a pharmaceutical product in Mauritius, and our registration application has not yet been completed. Until registration is granted, SS-31 (elamipretide) is supplied strictly for laboratory research use and is not sold, marketed or labeled as a medicine, supplement or treatment for any condition in any jurisdiction.
Tiger Blood Pharmaceuticals does not hold regulatory approval for SS-31 (elamipretide) in the United States, the European Union, the United Kingdom, or any other jurisdiction. Because this website is publicly accessible, customers are responsible for confirming that the purchase, import and use of this product is lawful where they live before placing an order.
This page will be updated once our Mauritius registration status changes.
Research Evidence
Elamipretide has been studied in formal clinical trials by its original developer for specific rare and cardiac conditions, with mixed results across different trials and endpoints. It remains an investigational drug with no FDA or equivalent approval anywhere, and is not established as safe or effective for general use.